HSCS
HeartSciences Inc. (HSCS) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
HSCS shows no durable profitability advantage, with TTM ROIC at -2.0%, leaving it structurally behind profitable peers that compound capital more efficiently.
The company’s only apparent strength is not evidenced in the provided metrics, so it lacks a peer-relative operating edge to support margin resilience.
No segment concentration or growth data are provided, preventing evidence of a defensible niche versus peers in demand or pricing power.
The available liquidity and leverage metrics are weak, so they do not translate into a structural strength relative to better-capitalized peers.
Weaknesses
HSCS’s current ratio of 0.50 and negative quick ratio indicate acute short-term liquidity stress, placing it below peers with more flexible working capital.
Net debt to EBITDA of 196.5x and debt-to-equity of 17.4x imply extreme balance-sheet leverage, materially constraining competitiveness versus less levered peers.
The cash conversion cycle is extraordinarily elevated, signaling severe working-capital inefficiency that weakens reinvestment capacity relative to peers.
Negative ROIC confirms capital is not earning its cost, so HSCS trails peers that can fund growth internally and preserve strategic optionality.
Opportunities
If HSCS can normalize working capital, the current liquidity gap could narrow quickly because peers with stronger cash cycles would otherwise retain a funding advantage.
Any deleveraging would have outsized strategic value, since reducing extreme leverage could improve access to capital versus similarly stressed peers.
Operational simplification could matter if it shortens the cash conversion cycle, because peers with tighter cash discipline typically sustain better resilience.
Absent segment data, opportunity likely depends on internal repair rather than market expansion, leaving HSCS behind peers with visible growth platforms.
Threats
Extreme leverage raises refinancing and dilution risk, making HSCS more vulnerable than peers with lower debt burdens and stronger creditor access.
Weak liquidity increases the chance of supplier or lender pressure, which can disrupt operations faster than in better-capitalized peer companies.
Negative ROIC suggests value destruction if conditions remain unchanged, while peers with positive returns can widen the competitive gap over time.
The very long cash conversion cycle can trap cash in operations, leaving HSCS less able than peers to absorb shocks or fund growth.
Overall Score
HSCS is structurally weak versus peers because extreme leverage, poor liquidity, and negative capital returns outweigh any identifiable competitive advantage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on HeartSciences Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
